CATALOGO DEI PRODOTTI DELLA RICERCA

SIMBOLO, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.350
EU - Europa 5.342
AS - Asia 3.777
SA - Sud America 498
Continente sconosciuto - Info sul continente non disponibili 232
AF - Africa 129
OC - Oceania 15
Totale 15.343
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.188
RU - Federazione Russa 2.154
SG - Singapore 1.299
CN - Cina 1.266
GB - Regno Unito 868
IT - Italia 794
BR - Brasile 379
HK - Hong Kong 356
DE - Germania 339
VN - Vietnam 309
SE - Svezia 283
IE - Irlanda 239
FR - Francia 221
FI - Finlandia 138
KR - Corea 123
CA - Canada 89
BD - Bangladesh 85
NL - Olanda 66
IN - India 62
JP - Giappone 50
UA - Ucraina 45
AR - Argentina 38
MX - Messico 38
ID - Indonesia 37
ES - Italia 35
TR - Turchia 33
PL - Polonia 31
AT - Austria 30
BE - Belgio 29
IQ - Iraq 29
NG - Nigeria 29
EC - Ecuador 22
BJ - Benin 18
CO - Colombia 18
PK - Pakistan 16
SA - Arabia Saudita 16
TG - Togo 16
ZA - Sudafrica 16
AU - Australia 14
MA - Marocco 14
UZ - Uzbekistan 12
VE - Venezuela 12
CL - Cile 10
IR - Iran 10
NP - Nepal 10
JO - Giordania 8
PH - Filippine 8
LT - Lituania 7
TN - Tunisia 7
UY - Uruguay 7
CH - Svizzera 6
CR - Costa Rica 6
EG - Egitto 6
KG - Kirghizistan 6
LV - Lettonia 6
MY - Malesia 6
AL - Albania 5
CZ - Repubblica Ceca 5
IL - Israele 5
NI - Nicaragua 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
TW - Taiwan 5
BB - Barbados 4
ET - Etiopia 4
JM - Giamaica 4
KE - Kenya 4
PT - Portogallo 4
PY - Paraguay 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BG - Bulgaria 3
EE - Estonia 3
GA - Gabon 3
GR - Grecia 3
HR - Croazia 3
MT - Malta 3
PA - Panama 3
PS - Palestinian Territory 3
RS - Serbia 3
BO - Bolivia 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
HU - Ungheria 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
NO - Norvegia 2
RO - Romania 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
Totale 15.091
Salva come PNG Salva come JPEG
Città #
Moscow 742
Southend 698
Singapore 681
Ashburn 644
San Jose 525
Chandler 507
Dallas 489
Hong Kong 345
Verona 337
Beijing 264
Dublin 235
Council Bluffs 210
New York 178
Ann Arbor 146
Woodbridge 144
Jacksonville 137
The Dalles 131
Munich 122
Los Angeles 116
Ho Chi Minh City 99
Jinan 86
Redmond 78
Lawrence 72
Princeton 72
Wilmington 68
Hanoi 66
Shenyang 63
Santa Clara 61
Helsinki 55
Nanjing 53
Houston 51
London 51
Milan 50
São Paulo 49
Columbus 46
Orem 46
Redondo Beach 46
Tianjin 46
Buffalo 43
Tokyo 42
Zhengzhou 41
Frankfurt am Main 36
Bologna 34
Hebei 33
Turku 33
Montreal 31
Brussels 29
Haikou 29
Abuja 28
Ningbo 28
Sindelfingen 28
Warsaw 28
Changsha 27
Hangzhou 27
Nanchang 26
Seoul 26
Guangzhou 25
Nuremberg 24
Phoenix 23
Seattle 23
Brooklyn 22
Mexico City 22
Amsterdam 21
Poplar 21
Taizhou 21
Vienna 21
Dearborn 20
Denver 20
Jakarta 19
Kent 19
Toronto 19
Chicago 18
Cotonou 18
Rome 18
Taiyuan 18
San Francisco 17
Shanghai 17
Falls Church 16
Jiaxing 16
Lomé 16
Atlanta 15
Boston 15
Haiphong 15
Naples 15
Rio de Janeiro 15
Dong Ket 14
Redwood City 14
Stockholm 14
Chennai 13
Da Nang 13
Falkenstein 13
Baghdad 12
Belo Horizonte 12
Johannesburg 12
Norwalk 12
Paris 12
Barnet 11
Lappeenranta 11
Piscataway 11
Washington 11
Totale 9.112
Salva come PNG Salva come JPEG
Nome #
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 305
Whole-genome landscape of pancreatic neuroendocrine tumours 287
DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples 284
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 258
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 249
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 242
Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing 234
A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics 229
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 229
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 221
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. 214
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 214
IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation 212
Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers 211
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 206
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 206
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 205
Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients 201
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers 195
Reporting tumor molecular heterogeneity in histopathological diagnosis 192
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 190
Comparative Lesions Analysis Through a Targeted Sequencing Approach 190
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma 188
H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology 187
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 184
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 179
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 178
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas 176
Next-generation sequencing for genetic testing of familial colorectal cancer syndromes 175
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 173
Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer 170
FrequentNRG1fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression 170
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance 168
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 167
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis 166
Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma 166
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR 165
Exosomal miRNA signatures of pancreatic lesions 164
Poorly Cohesive Gastric Cancers Showing the Transcriptomic Hallmarks of Epithelial-Mesenchymal Transition Behave Aggressively 162
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations 161
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 160
Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma 159
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 159
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 158
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 158
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 153
Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characterization 152
Long-term organoid culture of a small intestinal neuroendocrine tumor 152
Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma 152
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 152
Collapse of the Plasmacytoid Dendritic Cells compartment in advanced cutaneous melanomas by components of the tumor cell secretome 149
Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumours display divergent genomic and transcriptomic profiles 148
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy 146
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 142
Techniques and New Diagnostic Technologies (Limitations, Applications) 138
Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and CDKN2A/B Homozygous Deletion on Recurrence-Free Survival 138
An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide 137
An Insight on Functioning Pancreatic Neuroendocrine Neoplasms 135
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 134
Intraventricular Meningiomas: Clinical-Pathological and Genetic Features of a Monocentric Series 134
Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology 133
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 131
pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells 130
MULTIGENE MUTATIONAL PROFILING OF CHOLANGIOCARCINOMAS IDENTIFIES ACTIONABLE MOLECULAR SUBGROUPS 129
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 129
Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors 124
Atypical meningiomas with an immunohistochemical profile consistent with hypermetabolic or proliferative molecular groups show high mitotic index, chromosomal instability, and higher recurrence risk 122
Il profilo molecolare 121
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 120
Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients 120
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study 120
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities 119
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres) 118
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives 117
Ascl1 and OTP tumor expressions are associated with Disease-Free Survival in Lung Atypical Carcinoids 114
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 114
Tubulocystic Carcinoma of Bile Ducts: A Distinct Type of Cholangiocarcinoma Associated With Adenofibroma-type Lesions 111
MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma 111
New genomic landscapes and therapeutic targets for biliary tract cancers 109
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 108
Exceptional Response in BRAF p.V600E-Mutant Enteric-Type Adenocarcinoma of the Lung With Cutaneous Spread: A Case Report 108
Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC) 107
Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis 106
Pathology of Biliary Tract Cancers 104
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 103
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer 101
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 101
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 98
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 96
Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification? 96
Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 90
Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades 87
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms 81
Combined adenocarcinoma–atypical carcinoid of the lung. Targeted Next-Generation Sequencing (NGS) suggests a monoclonal origin of the two components 81
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 80
Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature 80
Hepatocellular Carcinoma Genetic Landscape 77
Exploring the molecular and biological background of lung neuroendocrine tumours 76
Lung carcinoid tumours: histology and Ki-67, the eternal rivalry 66
Oncocytic and spindle cell typical carcinoids of lung: different immunophenotype and biological behavior 50
Totale 15.217
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.723
article - articoli 50.557
book - libri 0
conference - conferenze 2.322
curatela - curatele 0
other - altro 1.378
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.466
Totale 111.446
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022520 0 0 44 70 44 18 36 51 37 17 58 145
2022/20231.484 88 172 112 256 127 351 16 84 198 17 34 29
2023/2024867 40 59 82 91 109 154 49 63 12 53 131 24
2024/20252.250 115 119 123 383 79 89 117 87 310 146 229 453
2025/20267.213 503 332 509 1.209 1.895 431 616 389 561 450 156 162
2026/2027372 122 248 2 0 0 0 0 0 0 0 0 0
Totale 15.343